Pharmatech to Attend American Society of Clinical Oncology’s 50th Annual Meeting

DENVER - May 8, 2014 - PRLog -- Between the end of May and the beginning of June, the world of clinical oncology is attentively focused on the advancements of cancer drugs as the American Society of Clinical Oncology (ASCO) meeting commences.

Pharmatech shall attend ASCO’s 50^th annual meeting this year and has been an annual participant of ASCO for 14 years. With over 26,000 oncology professionals attending in years past, the venue becomes a great opportunity to centralize meetings with industry professionals. The ASCO event is hosted in Chicago, Illinois and attracts a global audience.

This year, Pharmatech will focus on their newest contribution to clinical research, AccessPPM - a molecular screening program that is the next stage of the company’s evaluation to align cancer patients with complex oncology clinical trials.

With the world of clinical oncology beginning to focus on biomarker-driven clinical trials, or the genetic makeup of a tumor, AccessPPM will become an invaluable asset to clinical program managers to more efficiently manage the enrollment of clinical trials. Please visit Pharmatech at ASCO for additional information about AccessPPM (Booth #12162).

Rob Bohacs, CEO, stated, "We are excited to use ASCO to further introduce our AccessPPM program to sponsors as we officially launched the program in 2014, after years of investment. We are always eager to learn about the continuing evolution on the drug development programs and now we're able to help support the micro-targeted programs with AccessPPM and electronically match patients to clinical trials at a molecular level – it’s truly remarkable.”

Pharmatech, headquartered in Denver, Colorado, is a Site Management Organization (SMO) and Contract Research Organization (CRO) with a focus on oncology clinical research. Through an organized network of cancer clinics, the company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and promoting the inclusion of clinical trials in the spectrum of patient treatment options.